Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cytokine release syndrome with no neurotoxicity observed in our phase 2 study. We collected patient-reported outcomes (PROs)… Continue reading Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
Tag: Adaptive Immunity
Monoclonal antibody shows promise in slowing progression of ALS
New research reveals a type of monoclonal antibody already tested in certain forms of cancer may be a promising treatment in stopping the progression of amyotrophic lateral sclerosis, or ALS, a fatal neurodegenerative disease. The study, led by scientists at Oregon Health & Science University, published today in the Proceedings of the National Academy of… Continue reading Monoclonal antibody shows promise in slowing progression of ALS
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates
V2-glycan/apex broadly neutralizing antibodies (bnAbs) recognize a closed quaternary structure of the HIV-1 envelope glycoprotein. He, Ou et al. introduced HCDR3 regions of neutralizing antibodies targeting this epitope into a diverse repertoire of murine B cell receptors (BCRs). Upon vaccination, these edited B cells affinity matured and generated potent neutralizing sera, highlighting the potential of an HCDR3-focused vaccine approach.
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
A 61-year-old woman presented in November 2000 with chronic lymphocytic leukaemia (CLL). She was treated with fludarabine, mitoxantrone and dexamethasone, followed by chlorambucil from February 2001 to June 2002. She remained well until 2021, when she presented with a tonsillar mass that on biopsy showed small lymphocytic lymphoma (SLL). She received the anti-CD20 antibody rituximab,… Continue reading Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis
B-cell–depleting monoclonal antibodies (mAbs) have emerged as an arguably mechanistically dominant drug class in the multiple sclerosis (MS) disease-modifying therapy (DMT) armamentarium in recent years. As a group, they represent a high-efficacy treatment option for relapsing MS and offer some degree of efficacy in progressive forms of MS. Ocrelizumab remains the only DMT approved for… Continue reading New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis
First-in-class Small Molecule Inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators
RSC Med. Chem., 2023, Accepted ManuscriptDOI: 10.1039/D3MD00150D, Research ArticleSomaya Abdel-Rahman, Katarzyna Świderek, Moustafa GabrThe interaction of the inducible co-stimulator (ICOS) with its ligand (ICOSL) plays key roles in T-cell differentiation and activation of T-cell to B-cell functions. ICOS/ICOSL pathway is a validated target…The content of this RSS Feed (c) The Royal Society of Chemistry
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
Only limited efficacy of chimeric antigen receptor T (CAR-T) cell therapy is observed in acute myeloid leukaemia (AML) patients . CD123 and CLL-1 were highly expressed on AML cells . The proportions of T cell subsets and NK cells involved in anti-tumour processes in patients significantly decreased when compared with healthy donors . A possible… Continue reading Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
NF-κB subunits direct kinetically distinct transcriptional cascades in antigen receptor-activated B cells
Abstract The nuclear factor kappa B (NF-κB) family of transcription factors orchestrates signal-induced gene expression in diverse cell types. Cellular responses to NF-κB activation are regulated at the level of cell and signal specificity, as well as differential use of family members (subunit specificity). Here we used time-dependent multi-omics to investigate the selective functions of… Continue reading NF-κB subunits direct kinetically distinct transcriptional cascades in antigen receptor-activated B cells
From the Bench: Creative Approaches in Cancer Research
Improved patient outcomes come from new treatments. New treatments stem from successful clinical trials. Clinical trials build on discoveries made in the lab. And laboratory discoveries? Those rely on a vast array of assays and specialized technologies, combined with the ingenuity of bench scientists who devise, master, and apply these tools in creative ways to… Continue reading From the Bench: Creative Approaches in Cancer Research